JANUARY 8, 2026 –HOUMA, LA – Cardiovascular Institute of the South (CIS) and Terrebonne General Health System (Terrebonne General) are the first in Louisiana to use the AngioSafe Santreva™-ATK Endovascular Revascularization Catheter to...
JANUARY 8, 2026 –HOUMA, LA – Cardiovascular Institute of the South (CIS) and Terrebonne General Health System (Terrebonne General) are the first in Louisiana to use the AngioSafe Santreva™-ATK Endovascular Revascularization Catheter to...
Christopher K. Zarins, MD; Dainis Krievins, MD, PhD
A new strategy based on identifying patients with silent coronary ischemia using coronary CT-derived FFR together with proactive ischemia-targeted coronary revascularization shows promise in reducing adverse cardiac events.
A new strategy based on identifying patients with silent coronary ischemia using coronary CT-derived FFR together with proactive ischemia-targeted coronary revascularization shows promise in reducing adverse cardiac events.
The study will evaluate the safety and effectiveness of the Artero™ IVL system in treating peripheral arterial disease (PAD) and support FastWave's ultimate path to FDA clearance.
The study will evaluate the safety and effectiveness of the Artero™ IVL system in treating peripheral arterial disease (PAD) and support FastWave's ultimate path to FDA clearance.
In this video, Clinical Editor Craig Walker, MD, comments on an article from the September issue article entitled “Deep Vein Arterialization for No-Option Chronic Limb-Threatening Ischemia: An Overview of the LimFlow System and CLariTI Study."
In this video, Clinical Editor Craig Walker, MD, comments on an article from the September issue article entitled “Deep Vein Arterialization for No-Option Chronic Limb-Threatening Ischemia: An Overview of the LimFlow System and CLariTI Study."
Mike Watts, MD, FSIR, discusses his presentation on the use of wearables and artificial intelligence in the prevention and treatment of chronic limb-threatening ischemia.
Mike Watts, MD, FSIR, discusses his presentation on the use of wearables and artificial intelligence in the prevention and treatment of chronic limb-threatening ischemia.
Bret N. Wiechmann, MD, FSIR, FAHA; Mike Watts, MD, FSIR
Drs Bret Wiechmann and Mike Watts discuss the differences between hospitals, ambulatory surgery centers, and office-based labs when dealing with CLTI interventions.
Drs Bret Wiechmann and Mike Watts discuss the differences between hospitals, ambulatory surgery centers, and office-based labs when dealing with CLTI interventions.
Dr KJ Nagarsheth, Professor of Surgery, Division of Vascular Surgery, at the University of Maryland School of Medicine, offers a concise, real-world readout on the clinical and procedural value of the Artix thrombectomy system.
Dr KJ Nagarsheth, Professor of Surgery, Division of Vascular Surgery, at the University of Maryland School of Medicine, offers a concise, real-world readout on the clinical and procedural value of the Artix thrombectomy system.
Kyle S. Stumetz, winner of the 2025 CIO Young Investigator Award, discusses his study, “Absorbable Gelatin Hydrodissection in Oncologic Thermal Ablations: Initial Outcomes.”
Kyle S. Stumetz, winner of the 2025 CIO Young Investigator Award, discusses his study, “Absorbable Gelatin Hydrodissection in Oncologic Thermal Ablations: Initial Outcomes.”
During Thursday’s “Diagnosis and Imaging in CLTI” session, George Pliagas, MD, FACS, FRCSC, shared how IVUS has reshaped his approach to treating peripheral vascular disease.
During Thursday’s “Diagnosis and Imaging in CLTI” session, George Pliagas, MD, FACS, FRCSC, shared how IVUS has reshaped his approach to treating peripheral vascular disease.
Vascular surgeon Dr. Takahiro Tokuda, from Nagoya Heart Center in Japan, outlines new evidence comparing 2 contemporary revascularization options for heavily calcified femoropopliteal lesions
Vascular surgeon Dr. Takahiro Tokuda, from Nagoya Heart Center in Japan, outlines new evidence comparing 2 contemporary revascularization options for heavily calcified femoropopliteal lesions
Thomas Zeller, MD, from the Universitaets-Herzzentrum Freiburg, Bad Krozingen, Germany, presented the inaugural findings from the WOUND infection and clinical outcomeS IN patients with Chronic Limb-Threatening Ischemia (WOUNDSinCLTI) study,
Thomas Zeller, MD, from the Universitaets-Herzzentrum Freiburg, Bad Krozingen, Germany, presented the inaugural findings from the WOUND infection and clinical outcomeS IN patients with Chronic Limb-Threatening Ischemia (WOUNDSinCLTI) study,
During Wednesday morning’s “CLTI in 2025” session, interventional radiologist Jos van den Berg, MD, PhD, from the Clinica Luganese Moncucco in Lugano, Switzerland, delivered a presentation titled “The Economic Burden of CLTI in Europe.”
During Wednesday morning’s “CLTI in 2025” session, interventional radiologist Jos van den Berg, MD, PhD, from the Clinica Luganese Moncucco in Lugano, Switzerland, delivered a presentation titled “The Economic Burden of CLTI in Europe.”
Richard Neville, MD, outlines how CLTI programs are redefining “quality.” The era of anecdotal morbidity and mortality reviews has given way to continuous, data-driven evaluation aligned with value-based care.
Richard Neville, MD, outlines how CLTI programs are redefining “quality.” The era of anecdotal morbidity and mortality reviews has given way to continuous, data-driven evaluation aligned with value-based care.
Kak Khee Yeung, MD, from Amsterdam UMC in the Netherlands, gave a presentation at ISET 2025 that explored the integration of artificial intelligence into the treatment of peripheral arterial disease.
Kak Khee Yeung, MD, from Amsterdam UMC in the Netherlands, gave a presentation at ISET 2025 that explored the integration of artificial intelligence into the treatment of peripheral arterial disease.
At ISET 2025, Anvar Babaev, MD, PhD, presented findings from the Disrupt PAD BTK II study, a prospective, multicenter trial assessing the efficacy and safety of Shockwave IVL in treating calcified below-the-knee PAD.
At ISET 2025, Anvar Babaev, MD, PhD, presented findings from the Disrupt PAD BTK II study, a prospective, multicenter trial assessing the efficacy and safety of Shockwave IVL in treating calcified below-the-knee PAD.
The right clinical endpoint for assessing patency was discussed on Wednesday afternoon in a VIVA@LINC session by Raghu Kolluri, MD, System Medical Director at OhioHealth and President of Syntropic Core Lab in Ohio.
The right clinical endpoint for assessing patency was discussed on Wednesday afternoon in a VIVA@LINC session by Raghu Kolluri, MD, System Medical Director at OhioHealth and President of Syntropic Core Lab in Ohio.
Teri Yates, CEO of Accountable Physician Advisors and DocCentric Surgery Centers, delivered an in-depth presentation that provided a detailed comparison between OBLs and ASCs. She highlighted regulatory distinctions, facility requirements,...
Teri Yates, CEO of Accountable Physician Advisors and DocCentric Surgery Centers, delivered an in-depth presentation that provided a detailed comparison between OBLs and ASCs. She highlighted regulatory distinctions, facility requirements,...
Earl M. Johnson, Jr., MD, FACS, presented a discussion on the transformative role plastic surgery can play when incorporated early in a patient’s treatment plan. He emphasized that proactive, coordinated intervention significantly enhances...
Earl M. Johnson, Jr., MD, FACS, presented a discussion on the transformative role plastic surgery can play when incorporated early in a patient’s treatment plan. He emphasized that proactive, coordinated intervention significantly enhances...
Caroline E. Fife, MD, underscored how gaps in diagnosis coding, classification disagreements, and underreporting distort both prevalence and cost estimates, leading to inadequate attention and funding.
Caroline E. Fife, MD, underscored how gaps in diagnosis coding, classification disagreements, and underreporting distort both prevalence and cost estimates, leading to inadequate attention and funding.
Abigail Mize, BS, RDCS, RVT, gave a presentation entitled "Utilization of Ultrasound to Identify and Treat Complications." She emphasized that while prevention remains the best strategy, complications can arise even with the most skilled...
Abigail Mize, BS, RDCS, RVT, gave a presentation entitled "Utilization of Ultrasound to Identify and Treat Complications." She emphasized that while prevention remains the best strategy, complications can arise even with the most skilled...
During Thursday’s “Diagnosis and Imaging in CLTI” session, George Pliagas, MD, FACS, FRCSC, shared how IVUS has reshaped his approach to treating peripheral vascular disease.
During Thursday’s “Diagnosis and Imaging in CLTI” session, George Pliagas, MD, FACS, FRCSC, shared how IVUS has reshaped his approach to treating peripheral vascular disease.
Trisha Roy, MD, PhD, FACS, outlines why modern cross-sectional imaging performed before peripheral vascular intervention can be the difference between limb salvage and treatment failure in patients with CLTI.
Trisha Roy, MD, PhD, FACS, outlines why modern cross-sectional imaging performed before peripheral vascular intervention can be the difference between limb salvage and treatment failure in patients with CLTI.
Vascular surgeon Dr. Takahiro Tokuda, from Nagoya Heart Center in Japan, outlines new evidence comparing 2 contemporary revascularization options for heavily calcified femoropopliteal lesions
Vascular surgeon Dr. Takahiro Tokuda, from Nagoya Heart Center in Japan, outlines new evidence comparing 2 contemporary revascularization options for heavily calcified femoropopliteal lesions
Thomas Zeller, MD, from the Universitaets-Herzzentrum Freiburg, Bad Krozingen, Germany, presented the inaugural findings from the WOUND infection and clinical outcomeS IN patients with Chronic Limb-Threatening Ischemia (WOUNDSinCLTI) study,
Thomas Zeller, MD, from the Universitaets-Herzzentrum Freiburg, Bad Krozingen, Germany, presented the inaugural findings from the WOUND infection and clinical outcomeS IN patients with Chronic Limb-Threatening Ischemia (WOUNDSinCLTI) study,
JANUARY 8, 2026 –HOUMA, LA – Cardiovascular Institute of the South (CIS) and Terrebonne General Health System (Terrebonne General) are the first in Louisiana to use the AngioSafe Santreva™-ATK Endovascular Revascularization Catheter to...
JANUARY 8, 2026 –HOUMA, LA – Cardiovascular Institute of the South (CIS) and Terrebonne General Health System (Terrebonne General) are the first in Louisiana to use the AngioSafe Santreva™-ATK Endovascular Revascularization Catheter to...
The study will evaluate the safety and effectiveness of the Artero™ IVL system in treating peripheral arterial disease (PAD) and support FastWave's ultimate path to FDA clearance.
The study will evaluate the safety and effectiveness of the Artero™ IVL system in treating peripheral arterial disease (PAD) and support FastWave's ultimate path to FDA clearance.
JUNE 16, 2025 – HOUMA, LA – Cardiovascular Institute of the South (CIS) and Terrebonne General Health System (Terrebonne General) are the first in Louisiana to use the Spur® Peripheral Retrievable Stent System to treat chronic...
JUNE 16, 2025 – HOUMA, LA – Cardiovascular Institute of the South (CIS) and Terrebonne General Health System (Terrebonne General) are the first in Louisiana to use the Spur® Peripheral Retrievable Stent System to treat chronic...
NEW ORLEANS, LA, JUNE 6, 2025 – A large retrospective review of over 100,000 patients found the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in moderate peripheral artery disease (PAD) is associated with a decreased rate of...
NEW ORLEANS, LA, JUNE 6, 2025 – A large retrospective review of over 100,000 patients found the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in moderate peripheral artery disease (PAD) is associated with a decreased rate of...
May 24, 2024 – Lafayette, LA – Cardiovascular Institute of the South (CIS) is the first in the world to use the 200-cm RANGER Drug-Coated Balloon to treat peripheral artery disease (PAD) in the legs. CIS interventional cardiologist Dr....
May 24, 2024 – Lafayette, LA – Cardiovascular Institute of the South (CIS) is the first in the world to use the 200-cm RANGER Drug-Coated Balloon to treat peripheral artery disease (PAD) in the legs. CIS interventional cardiologist Dr....
The first patient in its ELITE-BTK pivotal trial was treated by Dr. Brian DeRubertis, FACS, Chief of the Division of Vascular & Endovascular Surgery at NewYork-Presbyterian and Weill Cornell Medicine in New York City.
The first patient in its ELITE-BTK pivotal trial was treated by Dr. Brian DeRubertis, FACS, Chief of the Division of Vascular & Endovascular Surgery at NewYork-Presbyterian and Weill Cornell Medicine in New York City.
Bloomington, Ind. — Cook Medical’s Zilver PTX drug-eluting stent (DES) has lower rates of in-stent occlusions among patients with restenosis at 3 years than Boston Scientific’s Eluvia DES, according to real-world data from the REALDES study....
Bloomington, Ind. — Cook Medical’s Zilver PTX drug-eluting stent (DES) has lower rates of in-stent occlusions among patients with restenosis at 3 years than Boston Scientific’s Eluvia DES, according to real-world data from the REALDES study....
The Auryon laser can be used to treat all infrainguinal lesion types, including above-the-knee (ATK), below-the-knee (BTK) and In-Stent Restenosis (ISR)3-6 and to date, it has been used to treat more than 100,000 patients7 in the United...
The Auryon laser can be used to treat all infrainguinal lesion types, including above-the-knee (ATK), below-the-knee (BTK) and In-Stent Restenosis (ISR)3-6 and to date, it has been used to treat more than 100,000 patients7 in the United...
Eric A. Secemsky, MD, MSc, lead investigator for the ELITE-BTK pivotal trial, said, “R3 Vascular’s novel approach in the design of its next generation bioresorbable drug eluting scaffold is of great interest to the physician community and has...
Eric A. Secemsky, MD, MSc, lead investigator for the ELITE-BTK pivotal trial, said, “R3 Vascular’s novel approach in the design of its next generation bioresorbable drug eluting scaffold is of great interest to the physician community and has...
Data showcased in two late-breaking clinical trial presentations at Paris Vascular Insights Course
PARIS – December 13, 2024 – Sensome, the pioneer of microsensing technology for instant intra-operative tissue analysis, today announced...
Data showcased in two late-breaking clinical trial presentations at Paris Vascular Insights Course
PARIS – December 13, 2024 – Sensome, the pioneer of microsensing technology for instant intra-operative tissue analysis, today announced...
MARLBOROUGH, Mass. and ALAMEDA, Calif. -- Boston Scientific Corporation and Penumbra, Inc., today announced the companies have entered into a definitive agreement under which Boston Scientific will acquire Penumbra in a cash and stock...
MARLBOROUGH, Mass. and ALAMEDA, Calif. -- Boston Scientific Corporation and Penumbra, Inc., today announced the companies have entered into a definitive agreement under which Boston Scientific will acquire Penumbra in a cash and stock...
JANUARY 8, 2026 –HOUMA, LA – Cardiovascular Institute of the South (CIS) and Terrebonne General Health System (Terrebonne General) are the first in Louisiana to use the AngioSafe Santreva™-ATK Endovascular Revascularization Catheter to...
JANUARY 8, 2026 –HOUMA, LA – Cardiovascular Institute of the South (CIS) and Terrebonne General Health System (Terrebonne General) are the first in Louisiana to use the AngioSafe Santreva™-ATK Endovascular Revascularization Catheter to...
First-of-its-Kind, Multi-Specialty Clinical Initiative Across IC, EP, Endovascular, Aortic, and Neurovascular
BIRMINGHAM, Ala. — January 8, 2025 — Rampart, a Birmingham, Alabama–based medical device company redefining interventional...
First-of-its-Kind, Multi-Specialty Clinical Initiative Across IC, EP, Endovascular, Aortic, and Neurovascular
BIRMINGHAM, Ala. — January 8, 2025 — Rampart, a Birmingham, Alabama–based medical device company redefining interventional...
The GORE® VIABAHN® FORTEGRA Venous Stent is engineered to offer an optimal balance of conformability and compression resistance for treating a broad range of patients.
FLAGSTAFF, Ariz. (January 6, 2026) — W. L. Gore & Associates’...
The GORE® VIABAHN® FORTEGRA Venous Stent is engineered to offer an optimal balance of conformability and compression resistance for treating a broad range of patients.
FLAGSTAFF, Ariz. (January 6, 2026) — W. L. Gore & Associates’...
MIDWAY 43 and MIDWAY 62 delivery catheters are designed to provide ideal tracking and a stable platform to support the delivery of various embolisation therapies in the neurovasculature.
MIDWAY 43 and MIDWAY 62 delivery catheters are designed to provide ideal tracking and a stable platform to support the delivery of various embolisation therapies in the neurovasculature.
The research suggests that CAVT, a technology designed to rapidly remove blood clots via microprocessor-controlled aspiration, has the potential to help reduce healthcare costs.
The research suggests that CAVT, a technology designed to rapidly remove blood clots via microprocessor-controlled aspiration, has the potential to help reduce healthcare costs.
Acquisition of SpectraWAVE’s next-generation technologies including HyperVueTM Imaging System with Enhanced Vascular Imaging for comprehensive, rapid, and AI-supported imaging inside the coronary arteries, and X1TM-FFR, an AI-enabled...
Acquisition of SpectraWAVE’s next-generation technologies including HyperVueTM Imaging System with Enhanced Vascular Imaging for comprehensive, rapid, and AI-supported imaging inside the coronary arteries, and X1TM-FFR, an AI-enabled...
The first pivotal trial implant of an investigational endovascular stent graft for the treatment of acute Type A dissections marks a critical milestone.
The first pivotal trial implant of an investigational endovascular stent graft for the treatment of acute Type A dissections marks a critical milestone.
Atrial fibrillation is rising at an alarming pace, and its clinical impact continues to deepen. Atrial fibrillation continues to expand in scale and complexity, with the Centers for Disease Control and Prevention estimating that 12.1...
Atrial fibrillation is rising at an alarming pace, and its clinical impact continues to deepen. Atrial fibrillation continues to expand in scale and complexity, with the Centers for Disease Control and Prevention estimating that 12.1...
New York, New York -- November 2025 -- Patrick E. Muck, MD, RVT, of TriHealth-Good Samaritan Hospital in Cincinnati, Ohio, presented new findings at the 2025 VEITHsymposium demonstrating that endovascular aortic repair (EVAR) can be...
New York, New York -- November 2025 -- Patrick E. Muck, MD, RVT, of TriHealth-Good Samaritan Hospital in Cincinnati, Ohio, presented new findings at the 2025 VEITHsymposium demonstrating that endovascular aortic repair (EVAR) can be...
